Core Insights - Establishment Labs Holdings Inc. reported a quarterly loss of $0.70 per share, which was better than the Zacks Consensus Estimate of a loss of $0.83, but worse than the loss of $0.58 per share from the previous year, indicating a 20.69% increase in loss year-over-year [1] - The company achieved an earnings surprise of 15.66% for the quarter, although it had a negative surprise of -58.06% in the previous quarter [1][2] - Revenue for the quarter was $41.38 million, slightly missing the Zacks Consensus Estimate by 0.06%, but showing a year-over-year increase from $37.17 million [2] Financial Performance - Over the last four quarters, Establishment Labs has surpassed consensus EPS estimates two times and topped revenue estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.55, with expected revenues of $51.88 million, while the estimate for the current fiscal year is -$2.05 on revenues of $208.6 million [7] Market Position - Establishment Labs shares have declined approximately 28.3% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] - The company's Zacks Rank is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Medical Services industry, to which Establishment Labs belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, PACS Group, Inc., is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of +10.5% [9]

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Core Insights - Cencora reported quarterly earnings of $4.42 per share, exceeding the Zacks Consensus Estimate of $4.08 per share, and up from $3.80 per share a year ago, representing an earnings surprise of 8.33% [1] - The company achieved revenues of $75.45 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.85% and increasing from $68.41 billion year-over-year [2] - Cencora has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.80 on revenues of $80.95 billion, and for the current fiscal year, it is $15.37 on revenues of $317.7 billion [7] - The trend of estimate revisions for Cencora is favorable, contributing to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Cencora belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Agilon Health (AGL) reported break-even quarterly earnings per share, surprising the market as the Zacks Consensus Estimate anticipated a loss of $0.01, marking a 100% earnings surprise [1] - The company posted revenues of $1.53 billion for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 1.73%, although this represents a decline from year-ago revenues of $1.6 billion [2] - Agilon shares have increased by approximately 116.8% since the beginning of the year, contrasting with a -3.9% decline in the S&P 500 [3] Earnings Outlook - The future performance of Agilon's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $1.47 billion, and for the current fiscal year, it is -$0.31 on revenues of $5.92 billion [7] Industry Context - The Medical Services industry, to which Agilon belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that tracking these revisions can provide insights into stock performance [5][6]

Core Viewpoint - LifeMD, Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, marking a significant improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 125% [1] Financial Performance - LifeMD posted revenues of $65.7 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.20%, compared to revenues of $44.14 million in the same quarter last year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have increased approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $64.9 million, and for the current fiscal year, it is $0.06 on revenues of $267.95 million [7] Industry Outlook - The Medical Services industry, to which LifeMD belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]

Pediatrix Medical Group (MD) Q1 2025 Earnings Call May 06, 2025 09:00 AM ET Speaker0 Certain statements and information during this conference call may be deemed to be forward looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward looking statements are based on assumptions and assessments made by Pediatrics' management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other fa ...

Premier, Inc. (PINC) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 41.94%. A quarter ago, it was expected that this company would post earnings of $0.29 per share when it actually produced earnings of $0.27, delivering a surprise of -6.90%.Over the last four quarters, the company ha ...

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32%. A quarter ago, it was expected that this physician group would post earnings of $0.37 per share when it actually produced earnings of $0.51, delivering a surprise of 37.84%.Over the last four quarters, t ...

Core Viewpoint - Fresenius Medical Care (FMS) is set to report its first-quarter 2025 results, with expectations of revenue growth and improved earnings per share compared to the previous year [1][9]. Performance Drivers - The FME25 transformation program has delivered EUR 567 million in cumulative savings, aiding in operational efficiencies across various functions [2][12]. - Positive momentum in U.S. same-market treatment growth was noted, with a 0.5% increase in the fourth quarter of 2024, indicating successful clinic operations [3][6]. Segment Analysis - The Care Enablement segment experienced a 10% organic revenue increase and a six-fold rise in operating income, reaching a margin of 7.8% [4][7]. - The Care Delivery segment showed stabilization with slight growth in treatment volumes, although it continues to face challenges from elevated mortality rates and labor shortages [6][5]. Financial Estimates - The Zacks Consensus Estimate for revenues is $5.25 billion, reflecting a 2.3% year-over-year growth, while earnings per share are estimated at $0.43, indicating a 19.4% improvement [9][10]. Long-Term Growth Potential - FMS aims for EUR 750 million in sustainable cost savings by the end of 2025, an increase from the previous target, with significant operational improvements already achieved [12]. - The upcoming launch of the FDA-approved 5008X Hemodiafiltration system is expected to enhance patient outcomes and drive growth [13]. Value-Based Care Strategy - The company is expanding its value-based care model through InterWell Health, managing over $11 billion in medical costs, with expectations of breakeven performance in 2025 [14].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average ...